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eEF2K [eEF2 (eukaryotic elongation factor 2) kinase]
phosphorylates and inactivates the translation elongation factor
eEF2. eEF2K is not a member of the main eukaryotic protein
kinase superfamily, but instead belongs to a small group of so-
called α-kinases. The activity of eEF2K is normally dependent
upon Ca
2+ and calmodulin. eEF2K has previously been shown
to undergo autophosphorylation, the stoichiometry of which
suggested the existence of multiple sites. In the present study
we have identiﬁed several autophosphorylation sites, including
Thr
348,T h r
353,S e r
366 and Ser
445, all of which are highly conserved
among vertebrate eEF2Ks. We also identiﬁed a number of other
sites,includingSer
78,aknownsiteofphosphorylation,andothers,
some of which are less well conserved. None of the sites lies in
the catalytic domain, but three affect eEF2K activity. Mutation of
Ser
78,T h r
348 and Ser
366 to a non-phosphorylatable alanine residue
decreasedeEF2Kactivity.PhosphorylationofThr
348 wasdetected
by immunoblotting after transfecting wild-type eEF2K into HEK
(human embryonic kidney)-293 cells, but not after transfection
with a kinase-inactive construct, conﬁrming that this is indeed a
site of autophosphorylation. Thr
348 appears to be constitutively
autophosphorylated in vitro. Interestingly, other recent data
suggest that the corresponding residue in other α-kinases is also
autophosphorylated and contributes to the activation of these
enzymes [Crawley, Gharaei, Ye, Yang, Raveh, London, Schueler-
Furman, Jia and Cote (2011) J. Biol. Chem. 286, 2607–2616].
Ser
366 phosphorylation was also detected in intact cells, but was
still observed in the kinase-inactive construct, demonstrating that
this site is phosphorylated not only autocatalytically but also in
trans by other kinases.
Key words: calmodulin, eukaryotic elongation factor 2 (eEF2),
elongation, α-kinase, mass spectrometry (MS), translation.
INTRODUCTION
eEF2K [eEF2 (eukaryotic elongation factor 2) kinase] is
aC a
2+/CaM (calmodulin)-dependent protein kinase, which
phosphorylates eEF2 on Thr
56 [1,2], decreasing the afﬁnity
of eEF2 for the ribosome and thereby inhibiting translation
elongation [3,4]. eEF2K contains two main identiﬁable domains:
thecatalyticdomainliesintheN-terminalhalfofthesequenceand
belongstothesmallgroupofso-calledα-kinaseswhichcomprises
six members in mammals [5–8]. Immediately N-terminal to this
liestheCaM-bindingregion[9,10].TheC-terminalpartofeEF2K
containsseveralfeatureswithpredictedα-helicalstructureandhas
similarity to the so-called ‘SEL1’ domains that are often involved
in protein–protein interactions [11].
Theα-kinasesarenothomologouswiththeclassicaleukaryotic
protein kinase superfamily. However, structural analysis of the
catalytic domain of one α-kinase, the TRP (transient receptor
potential)channelTRPM7(alsotermedChaK,forchannelkinase)
revealed similarity to the fold of other protein kinases [12].
Subsequent studies showed that the kinase domain of another
α-kinase, the Dictyostelium discoideum MHCKA (myosin heavy
chain kinase A) adopted a similar structure [13]. However, in
contrast with members of the classical protein kinase family, little
is known about the molecular mechanisms by which the activities
of α-kinases are regulated.
eEF2K is subject to control by phosphorylation by several
kinases which phosphorylate it in trans at sites in the ‘linker’
region between its N-terminal catalytic and C-terminal ‘SEL1’
domains [14–18]. In the presence of Ca
2+ and CaM, eEF2K
undergoes autophosphorylation on serine and threonine residues
[19].
Autophosphorylation of other protein kinases modulates their
activity. In particular, two α-kinases, TRPM6 and TRPM7,
undergo extensive autophosphorylation, which enhances their
catalytic activity [20–23]. MHCKA also undergoes substantial
autophosphorylation, which promotes its activation [24,25].
However, most of the autophosphorylated residues in these
proteins lie outside their catalytic domains and, of those that are
located within the kinase domain, several are not conserved in
eEF2K.
So far, there is no information on the identities of the auto-
phosphorylation sites in eEF2K or their functions. In the present
study we have identiﬁed the major sites of autophosphorylation
in mammalian eEF2K and demonstrate that at least three of them
modulate its activity. In particular, Thr
348, corresponding to an
autophosphorylated threonine residue in MHCKA, is important
for its catalytic activity and Ser
366, which has been described as
being a trans phosphorylation site in vivo [15], are important for
the activity of eEF2K in autophosphorylation and against some
substrates.
Abbreviations used: 2D, two-dimensional; CaM, calmodulin; eEF2, eukaryotic elongation factor 2; eEF2K, eEF2 kinase; ESI, electrospray ionization;
GST, glutathione transferase; HEK, human embryonic kidney; LC, liquid chromatography; MHCKA, myosin heavy chain kinase A; TRP, transient receptor
potential.
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EXPERIMENTAL
Materials
The MH-1 peptide RKKFGESEKTKTKEFL [9,24] was
synthesized by V. Stroobant (Ludwig Institute for Cancer
Research, Brussels, Belgium). All routine chemicals and
biochemicals were purchased from BDH-Merck and Sigma–
Aldrich, except for [γ-
32P]ATP, which was purchased from
PerkinElmer. Chromatography columns and TLC plates
were purchased from GE Healthcare, and the Ultracell
centrifugation system was from Amicon. The anti-phospho-
Ser
78 and -phospho-Thr
348 antibodies for eEF2K were generated
by Eurogentec. The anti-phospho-Ser
366 antibody was from Cell
Signaling Technology, as was the anti-eEF2K antibody. Anti-
FLAG antibody and alkaline phosphatase immobilized on beaded
agarose were from Sigma–Aldrich. Alkaline phosphatase and
trypsin were from Promega. Solvents and acids for HPLC
and LC (liquid chromatography)–MS were from Biosolve.
Molecular biology
The cDNA encoding human eEF2K was cloned into the vector
pGEX-6P [14]toallowefﬁcientexpressionasaGST(glutathione
transferase)-fusion protein in Escherichia coli or in PHM vector
for expression of FLAG-tagged eEF2K in HEK-293 cells.
Point mutations were created using the QuikChange® system
(Stratagene).
Protein preparations
Wild-type and mutant human recombinant GST–eEF2K were
expressed in E. coli BL21(DE3) cells by induction with 0.5 mM
isopropyl β-D-thiogalactopyranoside for 16 h at 18◦C. After
induction, bacteria were lysed in 50 mM Tris/HCl, pH 7.5,
300 mM NaCl, 1 mM dithiothreitol, 0.1% 2-mercaptoethanol,
0.5% Triton X-100, 0.5 mM PMSF, 0.5 mM benzamidine-
Cl, 5 nM leupeptin, 5 nM aprotinin, 0.02% Brij35 and
0.02% sodium azide. Bacterial lysates were ﬁrst puriﬁed
on DEAE-Sepharose (300–600 mM NaCl gradient) followed
by afﬁnity chromatography on glutathione–Sepharose. Puriﬁed
GST–eEF2K preparations in buffer containing 10% (v/v)
glycerol, 50 mM Tris/HCl, pH 7, 150 mM NaCl and 15 mM 2-
mercaptoethanol were concentrated by ultraﬁltration (Amicon
Ultracell system, 100 kDa cut-off). SDS/PAGE analysis of full-
lengthwild-typeGST–eEF2Kindicatedarelativemolecularmass
of 130 kDa, and the preparation was approximately 90% pure
(results not shown).
Dephosphorylation of recombinant eEF2K
Recombinant eEF2K (1 mg of protein/ml) was incubated at
room temperature (21◦C) with alkaline phosphatase immobilized
on agarose beads (approximately 3000 units/20 μl of reaction
mixture, where 1 unit corresponds to the amount of enzyme that
hydrolyses 1 μmol of p-nitrophenyl phosphate per min at pH 9.8
and 37◦C). After 20 min, the mixture was centrifuged at 1000 g
for 3 min to remove the immobilized phosphatase. Dephos-
phorylatedeEF2Kwasthendilutedinautophosphorylationbuffer.
Autophosphorylation of recombinant eEF2K
Recombinant eEF2K (50 μg/ml) was incubated with Ca
2+/CaM
(0.2 mM/10 μg/ml) and 0.1 mM [γ-
32P]MgATP (1000 c.p.m./
pmol) in 40–120 μl of phosphorylation buffer [26] at 30◦C.
At various times, aliquots (10 μl) were taken for analysis by
SDS/PAGE in 10% (w/v) mini-gels. Bands corresponding to
eEF2K were cut directly from the gel and dissolved in vials
containing 500 μlo f3 % (w/w) H2O2 by heating for 2 h at
80◦C prior to liquid scintillation counting. Stoichiometries of
32P
incorporation were calculated as described previously [27].
Phosphorylation site identiﬁcation by tandem MS, database
searching and analysis
For phosphorylation site identiﬁcation, wild-type and mutant
GST–eEF2K preparations (5 μg) were incubated in a ﬁnal
volume of 40 μl with Ca
2+/CaM (0.2 mM/10 μg/ml) and
0 . 1m M[ γ-
32P]MgATP. After 60 min, the reactions were stopped
for trypsin digestion and HPLC [28]. Radioactive peaks were
concentrated and analysed by nanospray ESI (electrospray
ionization)–MS [28]. Alternatively, phosphopeptides were
analysed by LC–tandem MS with the LTQ XL equipped with
a microﬂow ESI source interfaced to a Dionex Ultimate Plus
Dual gradient pump, a Switchos column switching device and
Famos Autosampler (Dionex). Separation was performed on a
Hypercarb column (180 μm×15 cm; Thermo Fisher Scientiﬁc)
equilibrated in solvent A [5% (v/v) acetonitrile and 0.05%
formic acid in water] using a gradient from 0 to 70% solvent B
[80% (v/v) acetonitrile and 0.05% formic acid in water] over
90 min at a ﬂow rate of 1.5 μl/min. The mass spectrometer was
operated in the data-dependent scan routine for the top ﬁve ions
with an MS scan range of m/z 300–2000. MSA (Multi Stage
Activation) was enabled for a phosphate neutral loss of 98, 49 or
32.66 with respect to the precursor m/z [29].
Peak lists were generated using the application spectrum
selector in the Proteome Discoverer 1.2 package. From raw
ﬁles, tandem MS spectra were exported as individual ﬁles in
.dta format with the following settings: peptide mass range, 400–
3500 Da; minimal total ion intensity, 500; and minimal number
of fragment ions, 12. The resulting peak lists were searched
using Sequest against a home-made protein database containing
the human eEF2K sequence (Uniprot O00418) and the GST
tag. The following parameters were used: trypsin was selected
with proteolytic cleavage only after arginine and lysine residues;
the number of internal cleavage sites was set to two; the mass
tolerance for precursor and fragment ions was 1.1 Da and
1.0 Da respectively; and the dynamic modiﬁcations considered
were +15.99 Da for oxidized methionine residues and +79.96
Da for phosphate addition to serine, threonine or tyrosine
residues. Peptide matches were ﬁltered using charge-state against
cross-correlation scores (xcorr) and phosphorylation sites were
validated manually.
2D (two-dimensional) peptide mapping
2D peptide mapping of tryptic peptides from autophosphorylated
eEF2K preparations radiolabelled in vitro was carried out
as described previously [30], except that detection was by
autoradiography and digestion was performed using trypsin in
the presence of the reducing agent tris(2-carboxyethyl)phosphine
at a ﬁnal concentration of 5 mM. For MS analysis, spots were cut
from the TLC plates and the cellulose was scraped into tubes for
peptide elution with 80 μlo f7 0 % (v/v) acetonitrile and 0.2%
formic acid by overnight incubation at room temperature. After
centrifugation, the supernatants were concentrated to 10 μl under
vacuum for LC–tandem MS analysis as described above.
eEF2K assay
The activity of eEF2K was measured using the ‘MH-1 peptide’ as
a substrate. This peptide is based on the sequence around the site
in Dictyostelium myosin heavy chain that is phosphorylated by
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someα-kinases[24]andalsobyeEF2K[9].Wild-typeandmutant
eEF2K preparations (2 μg) were allowed to autophosphorylate in
the presence of 0.1 mM non-radioactive MgATP in a ﬁnal volume
of 20 μl of phosphorylation buffer [26] at 25◦C rather than 30◦C
to limit thermal inactivation. After 60 min of incubation, aliquots
(2.5 μl)weretakenfortheeEF2Kassayinaﬁnalvolumeof50 μl
containing 0.1 mM MH-1 peptide and 0.3 mM [γ-
32P]MgATP
(500c.p.m./pmol)at30◦C.Aliquots(10 μl)weretakenatvarious
times up to 10 min of incubation for measurements of initial
rates of
32P incorporation [28]. A protein kinase activity of
1 unit corresponds to the amount of enzyme that catalyses the
incorporation of 1 nmol/min of
32P under the assay conditions.
The activity of eEF2K against eEF2 was measured essentially as
described previously [16], except that eEF2K was pre-incubated
with non-radioactive MgATP to allow autophosphorylation to
occur, prior to addition of eEF2 and [γ-
32P]MgATP. Samples
were then taken for analysis by SDS/PAGE/autoradiography at
the indicated times.
Cell culture and immunoblotting
HEK (human embryonic kidney)-293 cells were cultured and
transfected as described previously [31,32]. Immunoblotting
was performed as described previously [33], except that
detection used a LiCor Odyssey instrument rather than enhanced
chemiluminescence.
Protein estimation and statistical analysis
Protein concentrations were determind as described previously
[34] using BSA as the standard. The results are expressed
as the means+ −S.E.M. for the indicated number of individual
experiments. The statistical signiﬁcance of the results was
assessed by two-way ANOVA followed by a Bonferroni post-
test.
RESULTS
Recombinant eEF2K undergoes extensive autophosphorylation
Redpath and Proud [19] showed previously that native
eEF2KfromrabbitreticulocytesundergoesextensiveCa
2+/CaM-
dependent autophosphorylation. Consistent with this, recomb-
inant human eEF2K expressed in E. coli also underwent
autophosphorylation in a strictly Ca
2+/CaM-dependent manner
(Figure 1A). Autophosphorylation was time-dependent, reaching
8.05+ −0.86 (means+ −S.E.M., n=3) mol of phosphate
incorporated/mol of eEF2K after incubation at 30◦Cf o r
60 min. Prior dephosphorylation of the eEF2K preparation with
immobilized alkaline phosphatase resulted in a stoichiometry of
autophosphorylation that was slightly less than was observed
with the untreated enzyme after 60 min of incubation, perhaps
owing to slight protein denaturation during treatment (results
not shown). Also, the tryptic phosphopeptide maps of alkaline-
phosphatase-treated against untreated wild-type eEF2K obtained
after
32P-autophosphorylation were similar in terms of spot
distribution and intensity (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/442/bj4420681add.htm). In the
absence of Ca
2+/CaM, the stoichiometry of eEF2K phosphoryla-
tion was only 0.31+ −0.03 (means+ −S.E.M., n=3), indicating
that autophosphorylation is strongly Ca
2+/CaM-dependent. This
is similar to our results from previous studies [19].
In a recent parallel study, we expressed fragments of eEF2
containing the N-terminal and kinase domains (eEF2K[1–
402]) and the C-terminal region including the SEL1 domains
Figure 1 Recombinant eEF2K undergoes Ca2+/CaM-dependent auto-
phosphorylation
(A) GST–eEF2K was incubated with [γ-32P]ATP in the presence or absence of Ca2+/CaM
as described in the Experimental section. At the indicated times, samples were analysed by
SDS/PAGE for measurements of 32P incorporation. The values are means+ −S.E.M. (n=3).
(B) Autophosphorylation was measured as in (A) with the indicated concentrations of wild-type
(WT) eEF2K and eEF2K[S78A] mutant.
(eEF2K[478–725]) in E. coli [35]. The eEF2K[1–402]
fragment itself underwent autophosphorylation and was able to
phosphorylate the eEF2K[478–725] fragment [35], although, as
expected, the latter did not autophosphorylate itself (results not
shown). Taken together, these data indicate that the 1–402 and
478–725 regions each contain one or more autophosphorylation
site(s). A kinase-inactive mutant, eEF2K[K170M], did not
undergo autophosphorylation, as expected [35]. The rate of auto-
phosphorylation of recombinant eEF2K was independent of the
concentration of eEF2K in the assay (Figure 1B), both for
wild-type eEF2K and for a selected autophosphorylation site
mutant, eEF2K[S78A]. This indicates that autophosphorylation
occurs as a cis intramolecular event, since if different eEF2K
proteins phosphorylated each other in cis, the rate would
show a marked dependence upon concentration. These results
are consistent with our previous observations for the native
protein from rabbit reticulocytes [19], therefore indicating that
cis-autophosphorylation is not merely a consequence of the
expression of eEF2K as a GST-fusion protein in E. coli.I ti s
noteworthy that TRPM7, another member of the α-kinase family,
was also shown to form dimers (at least for the catalytic domain)
[12,36] and another study [37] indicated that recombinant eEF2K
is monomeric.
Identiﬁcation of autophosphorylation sites in eEF2K by tandem MS
and 2D peptide mapping
We used two complementary experimental approaches to identify
autophosphorylation sites in eEF2K, together with information
on its speciﬁcity [38]. eEF2K shows a very strong preference
for threonine over serine residues when assayed using synthetic
peptide substrates (although Redpath and Proud [19] reported
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Figure 2 HPLC proﬁles of 32P-autophosphorylated wild-type and mutant eEF2K preparations following trypsin digestion
Tryptic phosphopeptides from autophosphorylated eEF2K were separated by reverse-phase HPLC as described in the Experimental section. The major radiolabelled peaks are indicated by roman
numerals. Phosphorylation sites detected in the peaks are summarized in Table 1 and discussed in the text. HPLC proﬁles are shown for wild-type (WT) eEF2K (A) and the eEF2K[S78A] (B),
eEF2K[T348A] (C), eEF2K[S366A] (D), eEF2K[S491A] (E) and eEF2K[S445A] (F)m u t a n t s .
stronger autophosphorylation on serine than threonine residues).
It also showed a marked preference for peptide substrates with
basic residues at the +1a n d+3 positions relative to the
phosphorylated residue [38] (although the main site for eEF2K in
eEF2, Thr
56, only contains a basic residue at the +3 position).
In the ﬁrst experimental approach, we allowed recombinant
eEF2K to undergo autophosphorylation in the presence of
Ca
2+/CaM and [γ-
32P]MgATP. The radiolabelled protein was
then precipitated and digested with trypsin; the resulting peptides
were then resolved by reverse-phase HPLC. As shown in
Figure 2(A), nine peaks of radioactivity were reproducibly
observed (denoted ‘I’–‘IX’). Selected fractions from these peaks
were then subjected to tandem MS analysis to identify peptides
and pinpoint phosphorylation sites. The results are summarized
in Table 1. The number of peaks is broadly consistent with the
high stoichiometry of autophosphorylation observed, although
some peaks might arise from tryptic ‘missed cleavages’ due to
the presence of proline residues or to a phosphorylated residue
adjacent to the expected cleavage site. For example, peaks V and
VIII contain the same phosphorylated residue (Ser
366;s e eT a b l e1
for details).
Secondly, tryptic peptides from autophosphorylated radiola-
belled eEF2K were also separated by 2D mapping [ﬁrst
dimension, electrophoresis at pH 1.9 (separation by charge/mass
ratio); second dimension, chromatography (separation on the
basis of hydrophobicity)]. As shown in Figure 3(A), 12–13
different labelled peptides were observed, including seven major
species (termed ‘A’–‘G’ in Figure 3A) and several minor ones
(termed‘h’–‘m’).Toidentifyindividualsites,spotsfromtheTLC
plate obtained from tryptically digested
32P-autophosphorylated
wild-typeeEF2KwerecutoutandelutedfortandemMSanalysis.
Point mutations were then made in eEF2K, on the basis of
the tandem MS data and the information about the substrate
speciﬁcity of eEF2K. The HPLC/MS and TLC peptide mapping
experiments were then repeated using the mutant proteins and the
results were compared with those for the wild-type eEF2K.
For
32P-autophosphorylation studies of wild-type compared with
mutants for analysis by HPLC, the experiments were performed
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Table 1 MS analysis of peptides from HPLC peaks and TLC spots
LabelledfractionsfromautophosphorylatedGST–eEF2Kwild-typeandmutantHPLCruns(Figure2A)wereanalysedbynanosprayESI–tandemMSorLC–tandemMSasdescribedintheExperimental
section. Also, spots from TLC plates obtained after autophosphorylation and trypsin digestion of wild-type eEF2K, comparable with the separation pattern seen in Figure 3(A), were taken and eluted
for LC–tandem MS analysis. Phosphopeptides were identiﬁed either by multistage activation or by loss of 98 Da upon collision-induced dissociation. The phosphorylated residue (bold) was further
identiﬁed by fragmentation in MS3 mode. Residue numbering refers to the sequence of human eEF2K (Uniprot O00418) without the GST tag.
Peak Phosphopeptide sequence(s) from HPLC peaks Phosphorylation sites identiﬁed in HPLC peaks Phosphorylation sites identiﬁed in TLC spots*
IK 467YESDEDS474LGSSGR480 Ser474 Ser474 in spot E
II Y59YSNLTKS66ER68 and Y59YS61NLTKS66ER68 Ser66 and Ser61 Ser61 in spot B
III E434SENSGDSGYPS445EKRGELDDPEPR457 Ser445 Ser445 in spots G and l
IV L342LQSAKT348ILRGT353EEK356 and Y69SSSGSPANS78FHFK82 and L342LQSAKT348ILR351 Thr348, Thr353 and Ser78 Thr348 in spot A
VT 364LS366GSRPPLLR374 Ser366
VI W486NLLNS491SR493 Ser491
VII No identiﬁcation
VIII T364LS366GSRPPLLRPLSENSGDENMSDVTFDSLPSSPSSATPHSQK406 Ser366
IX No identiﬁcation
*See Figure 3(B) for the lettering of spots.
using the same stock of radioactive ATP and a correction factor
was applied to the results to take account of the radioactive
decay of
32P and for variations in protein amounts as judged by
overall UV absorbance of peaks, thereby allowing a quantitative
evaluation of any differences (Figure 2). The tryptic peptide
maps obtained with the
32P-autophosphorylated mutant eEF2Ks
compared with the
32P-autophosphorylated wild-type are not
quantitative but do provide a qualitative visualization of the
pattern of sites phosphorylated (Figure 4). Variations might arise
owing to differences in the amounts of material loaded on to
the plates, experiments being performed on different days and
exposure times for autoradiography.
PeakIfromtheHPLCproﬁleobtainedwithautophosphorylated
wild-type eEF2K (Figure 2A) corresponded to a peptide in which
Ser
474 was the phosphorylated residue identiﬁed by MS (Table 1).
The peptide contains a N-terminal lysine residue resulting from
a missed cleavage at an Arg-Lys sequence and a basic residue
only at position +6, which makes it a poor candidate for being
a bona ﬁde autophosphorylation site on the basis of previous
results [38]. Nevertheless, this site is perfectly conserved among
vertebrate eEF2Ks and is located in the ‘linker’ region. This site
has already been identiﬁed in vivo from EGF-stimulated HeLa
cells,butshowednotemporalchangeuponstimulation[39].Peak
I was lost in the HPLC proﬁle of the eEF2K[S474A] mutant,
whereas no other peaks changed (results not shown). Also, there
was no obvious change in the pattern of peptides on the 2D map
from the eEF2K[S474A] mutant (results not shown), suggesting
that this is a relatively minor site.
PeakIIcontainedtwoversionsofthesamepeptide,eithersingly
phosphorylated on Ser
66 or doubly phosphorylated on Ser
61 and
Ser
66. A smaller peptide containing only phosphorylated Ser
61
and eluting around fraction 6 was sometimes observed in the
HPLC proﬁle (Figures 2B, 2C and 2D). Ser
61 is not conserved in
mammalianeEF2Ksequences,andSer
66 isreplacedbyathreonine
residue in some species. Perhaps more importantly, although the
human sequence contains an arginine residue C-terminal to Ser
66,
most mammalian sequences do not. These observations suggest
that neither site is a conserved autophosphorylation site, and we
therefore did not study Ser
61 or Ser
66 further in the present study.
Peak III contained a very long (23 amino acids) tryptic peptide
with two internal missed cleavages at a consecutive Lys-Arg
sequence, and in which Ser
445 was the phosphorylated residue.
All vertebrate eEF2K sequences contain a serine residue at this
position, and in all cases it is followed by an arginine residue
at position +3 (and a lysine residue at +2). In view of the
Figure 3 2D peptide maps from autophosphorylated wild-type eEF2K
Wild-type eEF2K was allowed to undergo autophosphorylation in the presence of Ca2+/
CaMandthensubjectedtotrypticdigestion.Phosphopeptideswereresolvedbyelectrophoresis
and chromatography (polarity and directions are indicated). Also shown are the position of
the origin, where the peptide samples were applied, “X”, and the ﬁnal migration position
of the DNP–lysine marker (cross-hatched circle). (A) Representative map of wild-type eEF2K;
(B)schematicsummaryofpeptides;letteringincapitalsformajorpeptides(shownindarkgrey)
and in lower case for minor ones (light grey). The peptide shown by the dotted oval (‘m’) was
only observed on maps from the eEF2K[T348A] mutant.
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Figure 4 2D peptide maps from autophosphorylated wild-type eEF2K and
mutants
Wild-type or mutant eEF2K was allowed to undergo autophosphorylation in the presence
of Ca2+/CaM and then subjected to tryptic digestion. Phosphopeptides were resolved by
electrophoresisandchromatography(polarityanddirectionsareindicated).Thepositionswhere
the sample (larger ‘X’) and the DNP–lysine (smaller “x”) were applied, and the ﬁnal migration
position of the DNP–lysine marker (open circle) are also shown. The maps are derived from
wild-typeeEF2K(A),eEF2K[S445A](B),eEF2K[T348A](C),eEF2K[T353A](D),eEF2K[S491A]
(E), eEF2K[S366A] (F) and eEF2K[S78A] (G). The arrows highlight spots that were lost or that
decreased in intensity comparedwith the mapfrom wild-type eEF2K.All peptidemapswererun
at least twice to verify their reproducibility, and similar levels of radioactivity were applied.
highlyconservednatureofthissite,wecreatedaneEF2K[S445A]
mutant. The major phosphopeptide species ‘G’ and the minor
peptide ‘l’ were both absent from 2D maps derived from this
mutant, thus demonstrating that Ser
445 is indeed a signiﬁcant
site of autophosphorylation in eEF2K (Figure 4B; compare with
wild-type eEF2K in Figures 3A and 4A). HPLC analysis of the
tryptic peptides from the eEF2K[S445A] mutant revealed that
the labelling of peak III was abrogated, conﬁrming that this peak
does indeed correspond to this site (compare Figure 2A with 2F).
Moreover, Ser
445 was identiﬁed by MS in spots ‘G’ and ‘l’ after
peptide elution from the TLC plate of
32P-autophosphorylated
wild-type eEF2K (Table 1).
PeakIVwasthelargestsingleradioactivepeakintheproﬁleand
contained a mixture of three different phosphopeptides bearing
three phosphorylation sites, namely Thr
348,T h r
353 and Ser
78.
Thr
348 was seen in a singly phosphorylated peptide and, along
with Thr
353, in a doubly phosphorylated peptide due to a missed
cleavage (Table 1). We have previously identiﬁed Ser
78 as a site of
phosphorylation in eEF2K and made a phosphospeciﬁc antibody
for this site [33]. To ascertain whether this residue is indeed a
site of autophosphorylation, we incubated recombinant eEF2K
with non-radioactive MgATP for different times, and analysed
thereactionproductsbySDS/PAGEandimmunoblottingwiththe
anti-phospho-Ser
78 antibody. As shown in Figure 5(B), Ser
78 does
become phosphorylated during autophosphorylation, but only at
later times (roughly corresponding to the times when a mobility
shift is observed). Since the results in Figure 5(B) show that
Ser
78 undergoes autophosphorylation, we also ran 2D maps from
the eEF2K[S78A] mutant (Figure 4G). Although tryptic cleavage
should generate a readily mobile peptide containing this site
(YSSSGSPANpSFHFK), no obvious difference was seen relative
to the maps from wild-type eEF2K, indicating that this is only a
minor site of autophosphorylation. This was further conﬁrmed in
Figure 5 Use of phosphospeciﬁc antibodies to study the autophosphoryla-
tion of eEF2K in vitro and in intact cells
(A) Dot blot to establish whether the anti-phospho-Thr348 antibody is truly phosphospeciﬁc.
A total of 1 μl of the indicated dilutions of the phosphorylated and non-phosphorylated
versions of the corresponding peptide (10mg/ml) were applied to the membrane, which was
developed as for Western blot analysis. (B) Recombinant GST–eEF2K expressed in E. coli
was incubated without or with Ca2+/CaM, as indicated, and non-radioactive ATP for the times
shown. Samples were then analysed by SDS/PAGE followed by Western blot analysis with
the indicated antibodies speciﬁc for phospho (P)-Ser78, phospho-Ser366 or phospho-Thr348,
and anti-eEF2K antibody as a loading control. (C) Results for the phosphorylation of
Thr348 andSer366 invivo.HEK-293cellsweretransfectedwithavectorencodingeitherwild-type
(WT) eEF2K or the kinase-defective eEF2K[K170M] mutant. Cells were treated for the indicated
times with 2-deoxyglucose (DOG; 10mM; after transfer to medium containing 5 mM glucose),
chlorophenylthio-cAMP (CPT-cAMP; 0.5 mM) or forskolin (Forsk; 10μM); the latter two were
usedinthepresenceofisobutylmethylxanthine(1mM).CelllysateswereanalysedbySDS/PAGE
andimmunoblottingusingtheindicatedantibodies.C,control(untreated)cells.(D)Recombinant
GST–eEF2K was incubated, where noted, with non-radioactive MgATP and, in some cases,
Ca2+/CaM for the indicated times. Samples were then denatured and analysed by SDS/PAGE
and Western blotting using the indicated antibodies. (E) Recombinant GST–eEF2K was either
analyseddirectly(‘Noinc’)or incubatedwith alkalinephosphatase(+AP) for thetimes shown.
Samples were analysed by SDS/PAGE and Western blotting using the indicated antibodies. (F)
Wild-type eEF2K or two kinase-deﬁcient mutants (K/M, eEF2K[K170M]; D/A, eEF2K[D274A])
were analysed by SDS/PAGE and Western blotting using the indicated antibodies.
the HPLC proﬁle of the tryptically digested autophosphorylated
eEF2K[S78A] mutant (Figure 2B), which revealed that no
peaks were lost, but rather the extent of phosphorylation of all
peaks decreased, probably resulting from a decrease in kinase
activity (see below). Ser
78 is also conserved among vertebrate
eEF2K sequences.
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Table 2 Conservation of autophosphorylation sites in eEF2K
+, conserved; (+), local conservation weak, but residue probably conserved; −, local conservation strong, site not conserved; single letter code is used to indicate conservative replacements.
Species Ser61 Ser66 Ser78 Thr348 Thr353 Ser366 Ser445 Ser474 Ser491
Human + + + ++++++
Mouse + T + +++++−
Rat − T + +++++−
Cow + + + ++++++
Lizard (Anolis carolinensis) + + + +++++−
Zebra ﬁnch − T + ++++++
Zebraﬁsh − T + ++++++
Acorn worm (Saccoglossus kowalevskii) −−−+ S − T −−
Strongylocentrotus purpuratus − − − ++−−−−
Aplysia californica − − − +−−−+−
Ascaris suum −−− (+)S −− (+) −
Caenorhabditis elegans −−− (+) −−− (+) −
Loa loa −−−SS−−−−
Caenorhabditis briggsae −−− (+) −−− (+) −
Peak IV also contained peptides phosphorylated on Thr
348
and/or Thr
353.T h r
348 is conserved in almost all known eEF2K
sequences [in Loa loa (ﬁlarial nematode) it is replaced by a
serine residue], whereas othermammalian eEF2Ksequences,and
some other species, contain a threonine residue at the position
corresponding to Thr
353 in human eEF2K (Table 2). We therefore
also created eEF2K[T348A] and eEF2K[T353A] mutants. 2D
phosphopeptide mapping of the eEF2K[T348A] mutant showed
thattheintensitiesofspots‘A’,‘B’and‘C’decreased(Figure4C),
whereas a new spot (‘m’) appeared (indicated in Figure 4C).
After eluting peptides from spots cut from the TLCplate obtained
after
32P-autophosphorylation of wild-type eEF2K, we were able
to identify Thr
348 in spot ‘A’ and Ser
61 in spot ‘B’ by MS
(Table1).However,usingMSanalysis,wewereunabletoidentify
any sites in phosphopeptides eluted from spots ‘C’ and ‘m’.
The HPLC proﬁle from the autophosphorylated trypsin-digested
eEF2K[T348A] mutant (Figure 2C) was very different from the
proﬁle seen with wild-type eEF2K, in that peaks IV, V and VI
were all absent. Taken together, the results indicate that mutation
of Thr
348 to an alanine residue also affects the phosphorylation
of other less prominent sites (Ser
61,S e r
78 and Ser
491). This
probably reﬂects the large decrease in activity observed for
the eEF2K[T348A] mutant (see below). Also, because Thr
348
immediately follows a potential tryptic cleavage site (Lys
347),
the tryptic cleavage patterns of autophosphorylated wild-type
and T348A mutant could be different. It is well known that the
presence of a phosphorylated residue on the C-terminal side of
a trypsin cleavage site can prevent tryptic cleavage [40]. This
could explain the generation of peptides containing more than
onephosphorylatedresidue,complicatingtheinterpretationofthe
HPLC and 2D mapping data. Taken together, the results indicate
that the Thr
348 site is present in spot ‘A’ and possibly also in spots
‘B’ and ‘C’ (Figure 3B). Thus Thr
348, a highly conserved residue,
is a major site of autophosphorylation, whose mutation to alanine
dramatically affects autophosphorylation at several other sites.
To study the phosphorylation of Thr
348, we generated a
phosphospeciﬁc antibody which showed clear speciﬁcity for
the phosphorylated against the non-phosphorylated peptide
containing Thr
348 (Figure 5A). As shown in Figure 5(B), Thr
348
phosphorylation in recombinant eEF2K was already detected
at zero time, and so Thr
348 phosphorylation probably occurs
extremely rapidly or during expression in E. coli.
2D mapping analysis of the autophosphorylated
eEF2K[T353A] mutant indicated that some of the peptides
that were absent from the maps for eEF2K[T348A] were
also absent from the maps of this mutant, i.e. peptides ‘B’
and ‘C’ (Figure 4D, compare with Figure 3B). In contrast,
for the autophosphorylated eEF2K[T353A] mutant, peptide
‘m’ did not appear on the map. Therefore the results suggest
that the Thr
353 site would be present in peptides migrating in
spots ‘B’, ‘C’ and ‘m’ (Figure 3B). The HPLC proﬁle of the
tryptically digested autophosphorylated eEF2K[T353A] mutant
showed no striking differences compared with the proﬁle seen
for autophosphorylated wild-type eEF2K (results not shown),
consistent with the fact that its mutation to alanine did not affect
eEF2K activity (see below).
In peak V, we detected phospho-Ser
366 in a peptide resulting
from tryptic cleavage at Arg-Pro. This might seem surprising
given that trypsin should not cleave next to proline. As such,
this residue would be expected to be located in a very long
tryptic peptide (residues 364–406), which was indeed found in
peak VIII. However, trypsin was recently reported to cleave
Arg-Pro or Lys-Pro bonds more frequently than was previously
thought [41]. The Ser
366 site is well conserved and already known
to be phosphorylated in vitro, and probably in vivo, by p70
and p90 ribosomal protein S6 kinases [15]. The availability
of a phosphospeciﬁc antibody for this site allowed us to
test whether it is indeed autophosphorylated. Immunoblotting
revealed that Ser
366 does become phosphorylated when eEF2K
is incubated with Ca
2+/CaM (Figure 5B). Therefore we studied
the autophosphorylation of the eEF2K[S366A] mutant further
by peptide mapping. This revealed that a number of peptides
were absent from the maps compared with wild-type eEF2K,
speciﬁcally spots ‘B’, ‘C’, ‘D’ and ‘F’, and the minor species
‘k’ and ‘l’ (Figure 4F; compare with Figure 3B). The fact that
mutation of this residue affects multiple peptides may again be
a consequence of the dramatic effect of mutation of this residue
to decrease kinase activity. The HPLC proﬁle of the tryptically
digested autophosphorylated eEF2K[S366A] mutant (Figure 2D)
revealedthatpeaksVandVIIIwereindeedlostcomparedwiththe
proﬁle from autophosphorylated wild-type eEF2K (Figure 2A),
conﬁrming the identiﬁcation of this site. Also, all other peaks
were notably decreased in the HPLC proﬁle of this mutant owing
to a substantial decrease in the eEF2K activity (see below).
Peak VI contained a peptide in which Ser
491 was the sole phos-
phorylation site. This residue is not well conserved in mammals,
being replaced, for example, by a proline residue in rodents.
Mutation of this residue to alanine had no clear effect on the 2D
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Figure 6 Autophosphorylation of wild-type and mutant eEF2K preparations and effects on eEF2K activity
(A)Thehistogramshowsstoichiometriesofautophosphorylationofthewild-type(WT)andmutanteEF2Kpreparationscalculatedafter60minofincubationand,in(B),atime-courseofphosphorylation
of wild-type against the selected mutants is shown. The results are means+ −S.E.M., n=3. (C) eEF2K wild-type and mutant preparations were allowed to autophosphorylate in the presence of
non-radioactive ATP as described in the Experimental section. After 60min of incubation, aliquots were taken for eEF2K assay with MH-1 as substrate. Activities calculated from initial rates
of 32P-incorporation are shown in the histogram. Values are means+ −S.E.M., n=3a n d* P <0.001 compared with the wild-type. (D) The wild-type and indicated mutant eEF2K preparations were
incubatedwith[γ-32P]ATPforautophosphorylationasdescribedintheExperimentalsection.Attheindicatedtimes,samplesweretakenforSDS/PAGEandautoradiography.Thebottompanelshows
a Western blot for eEF2K to conﬁrm that equal amounts of wild-type and mutant enzyme were used.
maps (Figure 4E), but did cause the loss of peak VI in the HPLC
trace and a general decrease in overall labelling (Figure 2E; com-
pare with Figure 6B) compared with the
32P-autophosphorylation
labelling proﬁle of wild-type eEF2K (Figure 2A).
We also generated mutants at several other potential
autophosphorylation sites chosen either because they were
sometimes seen in the tandem MS analysis (Ser
345 and
Ser
500) or because an arginine residue was present at the
+3 position (Ser
477 and Ser
627). However, the maps obtained
after tryptic digestion of autophosphorylated eEF2K[S345A],
eEF2K[S477A], eEF2K[S500A] and eEF2K[S627A] mutants
wereindistinguishablefromthoseobtainedwithwild-typeeEF2K
(results not shown), indicating that they are not signiﬁcant
sites of autophosphorylation (or do not actually undergo
autophosphorylation at all).
Ser
359 is a known site of phosphorylation in eEF2K (for p38
MAPKδ (mitogen-activated protein kinase δ)/SAPK4 (stress-
activated protein kinase 4) and Cdc2 (cell division cycle 2)
[14,16]) and is followed by arginine residues at positions +2a n d
+4, suggesting that it might be an autophosphorylation site. We
therefore used the relevant phosphospeciﬁc antibody to ascertain
whether it is a site of autophosphorylation, but no signal was
observed when eEF2K was incubated with Ca
2+/CaM, even after
45 minofincubation(resultsnotshown).Ser
359 doesnottherefore
appear to be a signiﬁcant site of autophosphorylation in eEF2K.
Stoichiometry of in vitro autophosphorylation and effects
on eEF2K activity
The time course of autophosphorylation of each mutant eEF2K
preparation was compared with that of the wild-type. Four
eEF2K mutant preparations displayed a similar stoichiometry of
32P-incorporation compared with the wild-type, measured after
60 min of incubation (Figure 6A): {eEF2K[WT], 8.05+ −0.86
mol of phosphate incorporated/mol of protein; eEF2K[S345A],
6.3+ −0.71 mol of phosphate incorporated/mol of protein;
eEF2K[T353A], 5.8+ −0.67 mol of phosphate incorporated/mol
of protein; eEF2K[S445A], 6.2+ −0.68 mol of phosphate
incorporated/mol of protein; and eEF2K[S474A], 8.1+ −0.87
mol of phosphate incorporated/mol of protein (means+ −S.E.M.,
n=3)}. These stoichiometries are in general agreement with
the extent of labelling seen in the HPLC proﬁles of the
mutants compared with wild-type eEF2K (results not shown).
The decreases in stoichiometry observed for eEF2K[S345A],
eEF2K[T353A] and eEF2K[S445A] (Figure 6A) were not
statistically signiﬁcant and probably reﬂect the loss of
32P
incorporation by mutation of the site.
Mutation of Ser
78 to alanine signiﬁcantly decreased the
stoichiometry of
32P-incorporation by approximately 50%
compared with the wild-type: the incorporation of
32P into the
eEF2K[S78A] mutant reached 4.01+ −0.41 mol of phosphate
incorporated/molofprotein(means+ −S.E.M.,n=3)(Figures6A
and 6B). The HPLC proﬁle of the eEF2K[S78A] mutant was
similar to that of the wild-type, except that the overall extent of
labelling was reduced (Figure 2B), suggesting that this mutation
decreases kinase activity. Since Ser
78 is located close to the
CaM-binding domain ([9], Figure 7), the observed decrease
could be due to an effect on CaM-induced activation. Three
other mutations each signiﬁcantly decreased the stoichiometry
of autophosphorylation by approximately 60% compared with
the wild-type (Figures 6A and 6B): eEF2K[T348A], 2.9+ −
0.34 mol of phosphate incorporated/mol of protein;
eEF2K[S366A], 2.6+ −0.3 mol of phosphate incorporated/mol
of protein; and eEF2K[S491A], 2.5+ −0.27 mol of phosphate
incorporated/mol of protein (means+ −S.E.M., n=3).
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Figure7 Locationofautophosphorylationsiteswithinthedomainstructure
of eEF2K
The layout of the eEF2K polypeptide is depicted schematically (and only roughly to scale).
The major sites of autophosphorylation identiﬁed in the present study are indicated (black
arrows),withminoronesshownbygreyarrows.Thedottedarrowindicatesthatphosphorylated
Thr348 may dock with the phosphate (P-) pocket in the C-terminal lobe of the catalytic domain
to promote eEF2K activity, similar to Thr825 in MHCKA [25]. See the Discussion for further
information.
To assess the effects of autophosphorylation on eEF2K activity
towardstheMH-1substratepeptide,eEF2Kwild-typeandmutant
preparations were pre-incubated for 60 min with MgATP at
21◦C prior to assaying eEF2K activity. The thermal stability
of the proteins was checked by measuring eEF2K activity
towards MH-1 before and after incubation. The eEF2K wild-
type and selected eEF2K[S78A] mutant preparations lost 10–
30%ofeEF2Kactivityduringpre-incubation(resultsnotshown).
The activity of eEF2K[S78A] towards MH-1 was decreased by
approximately 50% compared with the activity of eEF2K wild-
type (Figure 6C). Mutation of Thr
348 and Ser
366 to alanine had
more drastic effects, reducing eEF2K activity of the preparations
by approximately 90 and 95% compared with the wild-type
protein respectively (Figure 6C). To test whether mutation to
negatively charged residues might mimic autophosphorylation
at this position and perhaps create a more active form of
eEF2K, we created eEF2K[T348D] and eEF2K[T348E] mutants
and studied their activities. These two mutants, along with the
eEF2K[T348A] mutant, phosphorylated puriﬁed eEF2 poorly
compared with wild-type eEF2K, indicating that in this case
negatively charged residues do not mimic phosphothreonine at
this position (Figure 6D).
Autophosphorylation of eEF2K studied in intact cells using the
anti-phospho-Thr348 antibody
It was clearly important to study the phosphorylation of
Thr
348 in eEF2K in intact cells. To do this, HEK-293
cells were transfected with a vector encoding FLAG-tagged
eEF2K and 24 h later were treated with agents known to
activate eEF2K. Treating cells with 2-deoxyglucose depletes
ATP levels, and activates the AMP-activated protein kinase,
which in turn positively regulates eEF2K [18,42], whereas
chlorophenylthio-cAMPandforskolinbothcausetheactivationof
cAMP-dependent protein kinase, another positive regulator
of eEF2K [43,44]. Western blot analysis of lysates derived from
the transfected cells were probed with phospho-Thr
348 and FLAG
antisera. As shown in Figure 5(C), the level of phosphorylation
of Thr
348 is essentially the same in all cases for wild-type eEF2K,
indicating that it is phosphorylated under basal conditions.
We also made use of a mutant of eEF2K in which Lys
170 is
mutatedtomethionine:thisdecreasescatalyticactivityby>99%
[35].ThelevelofphosphorylationofThr
348 wasgreatlydecreased
for this mutant, being almost undetectable under most conditions
(Figure 5C). Importantly, this demonstrates that phosphorylation
of eEF2K at Thr
348 is autocatalytic. We also tested the state of
phosphorylation of Ser
366 using a phosphospeciﬁc antibody. As
shown in Figure 5(C), this site is still heavily phosphorylated
in the eEF2K[K170M] mutant, indicating that in vivo it is also
phosphorylated by other kinases, such as p70 and p90 ribosomal
protein S6 kinases [15].
Additional evidence that Ser78 and Thr348 are autophosphorylation
sites
We tested the abilities of selected eEF2K mutants to undergo
phosphorylation at Thr
348 in vitro. Mutation of Thr
353 to alanine
did not affect the phosphorylation of Thr
348 (Figure 5D). In
contrast,theeEF2K[S366A]mutantshowedgreatlyreducedbasal
phosphorylation of Thr
348 (Figure 5D), although phosphorylation
of this site did increase over time when this variant protein
was incubated with MgATP and Ca
2+/CaM. The reduced
autophosphorylation of this mutant is in line with its decreased
activity shown in Figure 6(C).
Toassesswhetherthesignalsobservedwiththephosphospeciﬁc
antisera truly reﬂected phosphorylation of the corresponding
residues, recombinant eEF2K produced by E. coli was treated
with alkaline phosphatase for various times prior to analysis
by Western blot. Alkaline phosphatase treatment decreased the
signal for phospho-Ser
78 and phospho-Thr
348, but not the signal
for phospho-Ser
366 (Figure 5E). These results indicate that Ser
78
andThr
348 arealreadyphosphorylatedbutthatthesignalforSer
366
may be due to reactivity of the antibody with non-phosphorylated
eEF2K. To study this further, we also analysed two mutants
of eEF2K in which catalytic activity is greatly diminished (by
>99%)b ym u t a t i o no fL y s
170 to methionine or Asp
274 to alanine
[35]. The signals for phospho-Ser
78 and phospho-Thr
348, but not
for phospho-Ser
366, were markedly decreased for both mutant
proteins (Figure 5F). This conﬁrms that the phosphate at Ser
78
andThr
348 isintroducedbyautophosphorylation,andisconsistent
with the phospho-Ser
366 antibody detecting the unphosphorylated
residue, although other explanations are possible.
DISCUSSION
Our results of the present study conﬁrm and expand earlier
ﬁndings [19] that eEF2K undergoes extensive Ca
2+/CaM-
dependent autophosphorylation. Importantly, we now identify
nine sites of autophosphorylation in human eEF2K, consistent
with the observed stoichiometry of approximately 8 mol of
phosphate/mol of enzyme and show that at least three of them
affect phosphorylation of the MH-1 substrate peptide.
Interestingly, our results reveal for the ﬁrst time that eEF2K
can use serine as well as threonine as a phosphoacceptor, at least
within the eEF2K polypeptide itself, whereas an earlier study
which employed peptides as substrates found that eEF2K exhib-
itedanoverwhelmingpreferenceforphosphorylationofthreonine
residuesinthatcontext[38].Indifferentspecies,thephysiological
substrate eEF2 always has a threonine residue at the position
corresponding to Thr
56 in human eEF2, never a serine residue.
That study also indicated that eEF2K strongly preferred to phos-
phorylate residues with basic amino acids at the +1a n d+3 po-
sitions. Consistent with this, six of the autophosphorylation sites
that we have identiﬁed in the present study have a basic residue in
close proximity to the C-terminal side [arginine residues at +3
(Thr
348,Ser
366 andSer
445)or+2(Ser
491 andSer
66,alessprominent
site), or lysine at +3( T h r
353)]; Ser
61 and Ser
78 also have a lysine
residue at +4. Finally, for Ser
474, the basic residue is located at
+6. Autophosphorylation does not require a basic residue at +1
(none of the autophosphorylation sites we have identiﬁed has a
basicresidueatthisposition,andneitherdoesThr
56 ineEF2itself).
Severalofthemajorphosphorylationsitesareconservedamong
vertebrate eEF2K sequences (Table 2), but only one, Thr
348,a
critical site for eEF2K activity, is generally conserved in other
phyla as well (e.g. arthropods, echinoderms, molluscs, cnidaria
and nematodes; it is replaced by another phosphoacceptor, serine,
in some nematodes).
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Mutation of Ser
78,T h r
348,S e r
366 or Ser
491 to an alanine residue
reduced the stoichiometry of autophosphorylation (Figures 6A
and 6B), but activity measured towards the MH-1 peptide was
mostdrasticallyreducedbymutationofThr
348 orSer
366.Ho we v er ,
thismaybetheconsequenceofdifferentmechanismsastheHPLC
proﬁles and activity measurements differ considerably for these
three mutants. One must also bear in mind that mutations may
alterthefoldingofeEF2Kandexerteffectsunrelatedtotheroleof
given residues as autophosphorylation sites. The T348A mutation
had a very marked impact on autophosphorylation and activity
against both the MH-1 peptide and eEF2. Thus Thr
348 may be
consideredasamastersitewhosephosphorylationisimportantfor
phosphorylation at the other sites. It should be noted that Thr
348 is
theautophosphorylationsitethatisclosesttothecatalyticdomain
and is also the most widely conserved one among known eEF2K
sequences from species as divergent as nematodes and sea slugs
(see further discussion of this site below).
Mutation of eEF2K Ser
366 to alanine decreased the extent
of overall
32P-incorporation (Figures 2A and 2D). This mutant
also showed a substantial decrease in activity towards the MH-1
peptide similar to that observed for the eEF2K[T348A] mutant.
Thus Ser
366 is important for kinase activity against the MH-1
peptide, although it does not apparently affect activity against
eEF2 itself [15].
Although the eEF2K[T348A] (and eEF2K[S366A]) mutant
proteins showed drastically reduced activities towards MH-
1 (Figure 6C), they still underwent autophosphorylation
(Figure6A),showinganimportantdifferencebetweenautokinase
activity and the ability to phosphorylate substrates in trans.
The results for the activity of the S366A mutant against the
MH-1 peptide are surprising given that earlier work found that
this mutant did not show a marked change in activity against
eEF2 itself [15]; this may reﬂect differences in the requirements
for phosphorylation of the MH-1 peptide and eEF2, which
are clearly distinct [35]. The eEF2K[S491A] variant showed
a similar behaviour to that of eEF2K[S366A] as regards its
impact on the level of autophosphorylation and the HPLC proﬁle,
but it is clearly different in terms of catalytic activity towards
MH-1, which was only slightly altered. This again indicates
that the autophosphorylation and transphosphorylation processes
against different substrates, although sharing common regulatory
mechanisms, also have speciﬁc requirements.
We have shown in a recent study that, although fragments
lacking the C-terminal part of eEF2K cannot phosphorylate
eEF2 or the MH-1 peptide, addition of the eEF2K[478–725]
fragment restores their ability to do so, and we suggest that
the C-terminal SEL1-containing region helps to recruit substrates
for phosphorylation by the kinase domain [35]. The sequence
connectingthetwodomainscontainsanumberofphosphorylation
sites for kinases that regulate the activity of eEF2K (e.g. Ser
359
[16], Ser
366 [15], Ser
396 [17] and Ser
398 [18]). It is possible
that phosphorylation of these sites affects eEF2K activity by
altering the conformation of the ‘linker’ region and thereby
the efﬁciency of the ‘coupling’ between the C-terminal and
kinase domains of eEF2K. In this context, it is notable that
mutation of Ser
366 markedly alters activity against the MH-1
peptide.
Interestingly, other α-kinases also undergo autophos-
phorylation. TRPM6 and TRPM7 contain many sites of
autophosphorylation [20] and MHCKA also undergoes auto-
phosphorylation [24,25]. Where known, many of these
autophosphorylation sites lie in regions that are not homologous
with eEF2K; of those that do lie in their homologous kinase
domains, only one corresponds to a potential phosphorylation
site in eEF2K (Ser
135), and we did not ﬁnd this as an
autophosphorylation site, even though it should yield a readily
detectable tryptic phosphopeptide. Crawley et al. [45] identiﬁed
several sites of autophosphorylation in MHCKA. Our ﬁnding in
thepresentstudythatThr
348 isamajorsiteofautophosphorylation
in eEF2K is precisely in accord with their data and predictions
[45]. These authors showed that Thr
825 is constitutively
autophosphorylated in MHCKA. This residue, the equivalent of
Thr
348 in eEF2K, lies just C-terminal to the catalytic domain. On
the basis of the crystal structure of its catalytic domain together
with biochemical data, they proposed that phosphorylated Thr
825
dockswithaphosphate-bindingpocketintheC-terminallobe,and
that this interaction stimulates the catalytic activity of MHCKA.
They suggest that a similar mechanism may operate in other
α-kinases [45]. The results of the present study are entirely
consistent with this; Thr
348, which we have identiﬁed as a major
site of autophosphorylation, lies close to, and on the C-terminal
side of, the catalytic domain, and, in common with Thr
825 in
MHCKA, is followed by a hydrophobic residue (isoleucine
in many vertebrate eEF2Ks; replaced by other branched-chain
residues in some other species). Both the phosphate-binding
pocket and the proposed ‘partner’ for the adjacent hydrophobic
residue are conserved among MHCKs and eEF2Ks. It thus
appears likely that autophosphorylation promotes the activity
of these enzymes in similar ways, through the interaction of a
constitutively phosphorylated threonine residue with a conserved
phosphate-binding region. Our observation that replacement of
Thr
348 with either a glutamate or aspartate residue generated
a catalytically inactive enzyme is in accordance with the data
of Crawley et al. [45], who found that adding phosphate or
phosphothreonine, but not glutamate or aspartate, could activate
a truncated version of MHCKA that lacks the region containing
Thr
825. It is interesting that Thr
348 is basally phosphorylated in
humancells;thisprobablyensuresthateEF2Kisalready‘primed’
and poised to phosphorylate eEF2.
A surprising ﬁnding from our studies is that eEF2K undergoes
autophosphorylation on two sites, which inhibit its activity, Ser
78
and Ser
366; both sites are phosphorylated in vivo in response to,
e.g., insulin in an mTORC1 (mammalian target of rapamycin
complex 1)-dependent manner [15,33]. An analogous situation is
found for the catalytic α-/β-subunits of AMP-activated protein
kinase, which autophosphorylate on Ser
485/Ser
491 [28]. However,
protein kinase B also phosphorylates this site, thereby decreasing
the activation of AMP-activated protein kinase by LKB1 [46].
Phosphorylation of Ser
78 impairs the interaction of eEF2K with
CaM[33],whereasphosphorylationofSer
366 impairsitsactivation
byCa
2+ ions[15].Bothofthesesitesarealsoautophosphorylated,
and, in the case of Ser
78, apparently only at a low level in vitro or
in vivo (results not shown). In contrast, the 2D peptide maps
show that Ser
366 is a major site of autophosphorylation. It is
possible that its slow phosphorylation serves to turn off eEF2K
afteritsactivationinresponsetocellularstresses,bydesensitizing
eEF2K to activation by Ca
2+/CaM, thereby allowing translation
elongation to resume.
In conclusion, the results from the present study reveal that
Thr
348, and presumably its autophosphorylation, are critical for
the ability of eEF2K to phosphorylate substrates in trans,h a v i n g
similar effects on the phosphorylation of the MH-1 substrate
peptide.TheseresultssuggestthatautophosphorylationofeEF2K
may be a prerequisite for the activity of eEF2K, in line with other
α-kinases that have been studied.
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Figure S1 2D autophosphorylation peptide maps of alkaline-phosphatase-
treated compared with untreated wild-type eEF2K
(A) Wild-type eEF2K was ﬁrst dephosphorylated with alkaline phosphatase and subsequently
allowed to undergo autophosphorylation in the presence of Ca2+/CaM as described in the
Experimental section of the main text. (B) Wild-type eEF2K phosphorylated in the presence of
Ca2+/CaMwithoutpre-treatment.Aftertrypticdigestion,phosphopeptideswereresolvedby2D
electrophoresisandchromatography(polarityanddirectionsareindicated).Thepositionswhere
the sample (larger ‘X’) and the DNP-lysine (smaller ‘x’) were applied, and the ﬁnal migration
position of the DNP–lysine marker (broken open circle) are also shown.
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